Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 26:36:51-53.
doi: 10.1016/j.jdcr.2023.03.025. eCollection 2023 Jun.

Vitiligo during dupilumab therapy

Vincenzo Picone  1 , Maddalena Napolitano  2 , Ginevra Torta  1 , Gabriella Fabbrocini  1 , Cataldo Patruno  3
Affiliations
Case Reports

Vitiligo during dupilumab therapy

Vincenzo Picone et al. JAAD Case Rep. .
No abstract available

Keywords: atopic dermatitis; dupilumab; vitiligo.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Eczematous and excoriated patches involving mainly to the scalp, neck, and back of the hands.
Fig 2
Fig 2
Hypopigmented macules all over the (A) nape of the neck, (B) scalp, and (C) back of the hands. Complete remission of vitiligo and atopic dermatitis from the (D) nape of the neck, (E) scalp, and (F) back of the hands.
See this image and copyright information in PMC

References

    1. Napolitano M., Fabbrocini G., Potestio L., et al. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatol Ther. 2022;35(8) - PubMed
    1. Halling A.S., Loft N., Silverberg J.I., Guttman-Yassky E., Thyssen J.P. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147. - PubMed
    1. Napolitano M., Nocerino M., Picone V., et al. Dupilumab for the treatment of atopic dermatitis in transplant patients: two case reports and literature review. Dermatol Ther. 2022;35(4) - PMC - PubMed
    1. Aschenbrenner D.S. New dupilumab indication for rare skin disease. Am J Nurs. 2023;123(2):26–27. - PubMed
    1. Takeoka S., Kamata M., Yokoi I., Takehara A., Tada Y. Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report. Acta Derm Venereol. 2021;101(10) - PMC - PubMed

Publication types